牛牛AI助理已提取核心訊息
On December 31, 2023, BlackRock, Inc., a Delaware-based investment management corporation, filed an amended Schedule 13G with the Securities and Exchange Commission (SEC), indicating a significant ownership stake in Merck & Co, a leading pharmaceutical company. The filing, which is a routine disclosure for entities holding more than 5% of a company's shares, shows that BlackRock owns approximately 201,836,434 shares of Merck & Co's common stock, representing an 8.0% stake in the company. This position grants BlackRock sole voting power over 182,531,000 shares and sole dispositive power over the entire 201,836,434 shares they own. The filing emphasizes that the shares were acquired in the ordinary course of business and not for the purpose of changing or influencing the control of Merck & Co. The disclosure was officially signed by Spencer Fleming, Attorney-In-Fact for BlackRock, Inc., on January 26, 2024.
On December 31, 2023, BlackRock, Inc., a Delaware-based investment management corporation, filed an amended Schedule 13G with the Securities and Exchange Commission (SEC), indicating a significant ownership stake in Merck & Co, a leading pharmaceutical company. The filing, which is a routine disclosure for entities holding more than 5% of a company's shares, shows that BlackRock owns approximately 201,836,434 shares of Merck & Co's common stock, representing an 8.0% stake in the company. This position grants BlackRock sole voting power over 182,531,000 shares and sole dispositive power over the entire 201,836,434 shares they own. The filing emphasizes that the shares were acquired in the ordinary course of business and not for the purpose of changing or influencing the control of Merck & Co. The disclosure was officially signed by Spencer Fleming, Attorney-In-Fact for BlackRock, Inc., on January 26, 2024.
2023年12月31日，總部位於特拉華州的投資管理公司貝萊德公司向美國證券交易委員會（SEC）提交了經修訂的附表13G，表示擁有領先製藥公司默沙東公司的大量股權。該文件是對持有公司5％以上股份的實體的例行披露，顯示貝萊德擁有默沙東公司約201,836,434股普通股，佔公司8.0％的股份。這一立場賦予貝萊德對182,531,000股股票的唯一投票權，以及對他們擁有的全部201,836,434股股票的唯一處置權。該文件強調，這些股份是在正常業務過程中收購的，不是爲了改變或影響默沙東公司的控制權。該披露由貝萊德公司事實律師斯賓塞·弗萊明於2024年1月26日正式簽署。
2023年12月31日，總部位於特拉華州的投資管理公司貝萊德公司向美國證券交易委員會（SEC）提交了經修訂的附表13G，表示擁有領先製藥公司默沙東公司的大量股權。該文件是對持有公司5％以上股份的實體的例行披露，顯示貝萊德擁有默沙東公司約201,836,434股普通股，佔公司8.0％的股份。這一立場賦予貝萊德對182,531,000股股票的唯一投票權，以及對他們擁有的全部201,836,434股股票的唯一處置權。該文件強調，這些股份是在正常業務過程中收購的，不是爲了改變或影響默沙東公司的控制權。該披露由貝萊德公司事實律師斯賓塞·弗萊明於2024年1月26日正式簽署。
有用
沒用